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Abstract
Background: Vaccinia virus, one of the best known members of poxvirus family, has a wide host range both in vivo and 
in vitro. The expression of Flt3 ligand (FL) by recombinant vaccinia virus (rVACV) highly influenced properties of the 
virus in dependence on the level of expression.
Results: High production of FL driven by the strong synthetic promoter decreased the growth of rVACV in 
macrophage cell line J774.G8 in vitro as well as its multiplication in vivo when inoculated in mice. The inhibition of 
replication in vivo was mirrored in low levels of antibodies against vaccinia virus (anti-VACV) which nearly approached 
to the negative serum level in non-infected mice. Strong FL expression changed not only the host range of the 
recombinant but also the basic protein contents of virions. The major proteins - H3L and D8L - which are responsible 
for the virus binding to the cells, and 28 K protein that serves as a virulence factor, were changed in the membrane 
portion of P13-E/L-FL viral particles. The core virion fraction contained multiple larger, uncleaved proteins and a higher 
amount of cellular proteins compared to the control virus. The overexpression of FL also resulted in its incorporation 
into the viral core of P13-E/L-FL IMV particles. In contrary to the equimolar ratio of glycosylated and nonglycosylated FL 
forms found in cells transfected with the expression plasmid, the recombinant virus incorporated mainly the smaller, 
nonglycosylated FL.
Conclusions: It has been shown that the overexpression of the Flt3L gene in VACV results in the attenuation of the 
virus in vivo.
Background
Vaccinia virus (VACV) is the best-studied member of the
Orthopoxvirus genus of the poxvirus family. It has a wide
host range and is able to infect cells of many different ori-
gins. VACV has played important roles in medicine and
biomedical research. As VACV highly stimulates both the
innate and adaptive arms of the immune system, it was
used as the vaccine for eradication of smallpox and
recently, the virus has been used as a live recombinant
vaccine for the induction of protective immune response
against many pathogens in experimental animals. VACV
genome consists of a of 190 kbp dsDNA encoding over
200 proteins. The non-essential genes are used for the
insertion of our gene of interest [1]. The resultant recom-
binant virus (rVACV) usually expresses foreign genes
without remarkable impact on viral infectivity. Recombi-
nant proteins are correctly posttranslationally modified,
properly localized or secreted from infected cells.
Flt3 ligand (FL) is a hematopoietic growth factor that
plays an important role in the life cycle of several blood
cells. It is produced by bone marrow stromal cells, T cells
and endothelial cells and by a number of organs including
spleen, ovary, testis, intestine and kidney. FL alone
induces differentiation of macrophages in CD34+ cell
culture and stimulates increase in dendritic cell numbers
[2-8]. When FL is administered to mice, hematopoietic
stem cells and progenitors in the bone marrow and spleen
are expanded and mobilized into the peripheral blood. FL
increases beta-1-integrins or P-selectin expression and
downregulates VCAM-1 on peripheral blood and folicu-
lar cells [9-13]. Moreover, the ligand acts in synergy with
other cytokines, including stem cell factor (SCF), granu-
locyte-macrophage colony-stimulating factor (GM-CSF)
and interleukins 3, 6, 7, 11 and 15. Stimulation by FL
leads to proliferation, differentiation, maintenance and
long-term reconstitution of primitive hematopoietic cells
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Page 2 of 15(both lymphoid and myeloid progenitors) [5,14-16]. FL
dramatically enhances the production of antibodies to
soluble antigens in vivo [17]. Systemic inoculation
enhances the production of IFN-γ, IL-12, GM-CSF and
IL-5 which results in increase of cytotoxic T lympho-
cytes, natural killer cells and dendritic cells in blood [18-
20].
Human FL shares high homology with mouse FL in
themino acid sequence, mainly in the extracellular part of
the molecule, and is able to activate mouse Flt3 receptor
[21]. The human Flt3L gene encodes a 235-amino acid
type I transmembrane protein consisting of four
domains: 1) an N-terminal 26-residue signal peptide, 2) a
156-residue extracellular domain, 3) a 23-amino acids
transmembrane domain, and 4) a 30-residue cytoplasmic
domain [4,15,22]. FL is expressed in membrane-bound
and soluble forms. The cytokine is biologically active
both in the transmembrane form and in the soluble form
that is thought to be released into the circulation from
the cell membrane by protease cleavage or is produced
directly as the alternatively spliced soluble isoform
[15,22-24]. The extracellular domain alone has been
shown to be sufficient for bioactivity [23]. FL exists in
both monomeric and homodimeric forms. Soluble FL can
be a noncovalently linked oligomer and contains six
cysteine residues in each molecule that apparently form
intramolecular disulfides. The integrity of the FL dimer
seems to be essential for bioactivity; moreover, the fusion
of two soluble FL molecules can increase the activity of
the ligand [25,26]. FL belongs to the family of short chain
helical cytokines where the three-dimensional structures
of five members, i.e. interleukin-4 (IL-4), IL-2, IL-5, GM-
CSF and MCSF, have been solved [27]. The FL monomer
has the most similar protein structure to IL-4 although
the effects on blood cells are of different type [25,28].
The FL receptor, Flt3 (Fms-Like Tyrosine kinase 3),
belongs to members of the class III receptor tyrosine
kinase family of transmembrane glycoproteins and is
structurally related to the c-kit (KIT), c-fms (FMS), and
platelet-derived growth factor (PDGF) receptors. The
receptor is expressed only in a limited number of tissues,
including the human bone marrow, thymus, spleen, liver,
and lymph nodes.
In this study, we examined the influence of FL produc-
tion on the life cycle of recombinant virus. We con-
structed two recombinant vaccinia viruses of the Praha
strain (clone P13) designed for the expression of the
human gene encoding a soluble isoform of FL (sFL). The
rVACVs were characterized and compared for their mul-
tiplication and virulence in vitro and in vivo, and for the
ability to ensure the secretion of FL from infected cells.
We found out that the FL overexpression substantialy
influenced the properties of rVACV. High production of
FL resulted in decreased rVACV multiplication in mac-
rophages and in mice. Biochemical and electron micro-
scopic analysis of the recombinant virions revealed
changes in the protein composition and incorporation of
FL into the virion core. We have shown that the overex-
pression of the Flt3L gene in VACV results in attenuation
of the virus in vivo.
Results
Virus multiplication and sFL production and localization in 
vitro
We prepared recombinant vaccinia viruses expressing the
gene for a soluble isoform of human Flt3 ligand (FL). In
the first instance, we determined FL production and virus
multiplication in vitro. The monolayers of CV1 cells were
infected with recombinant VACV at a MOI of 2.5 and
cells were cultured in the fresh medium. The medium
and cells were harvested at the indicated intervals (Fig 1).
The cells were frozen and thawed and the centrifuged
supernatant was removed from cell debris. Both, media
containing extracellular (e. c) virus and supernatants con-
taining intracellular (i. c) virus were used for determina-
tion of infectious virus or production of FL. Replication
of recombinant viruses was determined by plaque assay.
The concentration of FL was measured by ELISA test.
The overall multiplication of FL-expressing recombi-
nants and control virus in CV1 cells was similar (Fig. 1A);
however, the newly formed infectious particles of P13-E/
L-FL were retained in infected cells and released to the
medium at later intervals after infection as compared
with P13-H5-FL or control virus P13-E7. Similar rates of
viral multiplication in CV1 cells were also found for dou-
ble recombinant viruses expressing β-galactosidase gene
of E.coli (data not shown). The production of intracellular
and secreted FL was followed up to 72 h.p.i. (Fig. 1B). The
peak of FL production driven by the H5 promoter was at
18 h.p.i., whereas the production from the E/L promoter
increased gradually and high amount of FL was produced
up to very late intervals.
To determine the sites of production, intracellular stor-
age and transport of sFL protein in infected cells, the sFL
was detected by immunofluorescent staining. Confluent
cultures of CV1 and HeLa cells were infected with P13-
H5-FL or P13-E/L-FL or control virus at a MOI of 2 for
30 minutes, cultured in fresh medium and stained at sev-
eral time intervals. To compare the location of sFL pro-
tein expressed by rVACV and produced in the absence of
virus infection, 293T cells (6 × 104) were transfected with
the expression plasmid pBSC-FL (2.5 μg) where the
expression of the sFL gene was controlled by the strong
cytomegalovirus promoter. Transfected cells were pro-
cessed for fluorescent microscopy after 48 hours of culti-
vation. The localization of sFL in the transfected 293T
cells (Fig. 1C-a, b) had the same fluorescent pattern as in
the virus infected cells (Fig. 1C-c, d, e, f). The course of
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Figure 1 In vitro multiplication and sFL production by rVACV. Confluent CV-1cell cultures were infected with purified virus at a MOI of2.5 at 37°C 
for 1 hour, washed with PBS and the fresh medium was added. The medium and cells were collected, frozen and thawed, and cell debris was removed. 
The titers of the infectious virus (A) were determined in the medium and in the cell lysate. Total FL production was determined by ELISA (B). The col-
umns in all graphs represent the mean ± s.d. The intracellular location of sFL (C) in 293T cells (a, b) 48 h after transfection or in infected CV1 (c, d) and 
HeLa cells (e, f) 9 h after infection or in J774.G8 cells (g, h) 3 h after infection with P13-H5-FL (c, e, g) or P13-E/L-FL (d, f, h) as visualized by an immu-
nofluorescent microscope at a magnification of 1000×. The colocalisation of sFL (D) with endoplasmic reticulum marker calreticulin or with cis-Golgi 
marker GM130 in HeLa cells 3 h after infection as visualized by an immunofluorescent microscope at a magnification of 1000×.
Zurkova et al. Virology Journal 2010, 7:109
http://www.virologyj.com/content/7/1/109
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time with strength of expression directed by the H5 or E/
L promoter (not shown). The H5 promoter was stronger
in early phase of infection and the fluorescent signal was
already visible at 3 hours after infection while the expres-
sion driven by the E/L promoter was hardly observable.
The signal of the sFL expression controlled under the E/L
promoter was stronger at later time intervals (followed up
to 12 h.p.i.) when the signal from P13-H5-FL infected
cells did no more rise (not shown). When we stained the
specific markers for cellular organels, calreticulin and
GM130, we observed the sFL protein localized mainly in
the endoplasmic reticulum (Fig. 1D-a). The colocalisation
of sFL with the cis-Golgi marker GM130 (Fig. 1D-b) was
not so obvious in infected cells and decreased in time due
to a massive transition of GM130 to viral factories. The
considerable portion of sFL seemed to be transported in
the vesicles toward the cell surface.
Multiplication of P13-E/L-FL in vivo as well as in 
macrophage cell line J774.G8 is impaired
To determine the influence of FL expression on viral mul-
tiplication in vivo, we infected mice intraperitoneally with
1 × 106 pfu of rVACV. The ovaries and blood serum were
collected at 24-hours intervals. The virus in ovaries was
determined by plaque assay of tissue homogenate or as
viral DNA by quantitative PCR. The level of FL was mea-
sured by ELISA in diluted sera.
The amount of virus (Fig. 2A) and viral DNA (Fig. 2B)
in the ovaries was increasing from the time of inoculation
to day 4 and then dropped. The comparison of multipli-
cation between different viruses showed that the expres-
sion of the FL gene did not affect multiplication of P13-
H5-FL virus, whereas the growth of P13-E/L-FL virus was
impaired in mouse ovaries, contrary to the situation in
CV1 cells in vitro. Similarly, serum FL was higher in ani-
mals infected with P13-H5-FL virus in comparison with
P13-E/L-FL (Fig. 2C). The highest amount of FL in the
serum was found on day 4 after infection in accordance
with the strongest virus replication in mouse ovaries. The
decreased serum FL levels reflected the impaired replica-
tion of the recombinant virus expressing FL under the
control of the E/L promoter as detected in the mouse
ovaries.
In order to determine the impact of the attenuation of
in vivo multiplication of P13-E/L-FL on its ability to
induce immune response, we measured the amount of
IgG1 and IgG2a specific for VACV by ELISA (Fig. 2D) in
the mouse sera 5 weeks after virus inoculation. We
observed that the multiplication of viruses correlated
with the level of anti-VACV antibodies. P13-E/L-FL
induced no detectable IgG1 or IgG2a antibodies against
the vaccinia antigen, whereas P13-H5-FL and P13-E7
elicited anti-VACV specific antibodies predominantly of
IgG2a isotype as expected for the immune response
against vaccinia virus infection.
To find an in vitro model for the study of in vivo inhibi-
tion of P13-E/L-FL replication, we compared the ability
of recombinants expressing sFL to multiplicate in cell
lines of various origin such as mouse J774.G8 mac-
rophages, 32D cells, human HeLa cells or MOLM-9 leu-
kemic cells. We infected cells at a MOI of 1 with double
recombinant viruses expressing FL or HPV16 E7,
together with β-galactosidase serving as a reporter gene
for relative multiplication of viruses. The infected cells
were incubated with or without cytosine arabinoside (40
μg/ml) to block viral DNA synthesis and consequently to
prevent late gene expression [29]. The β-galactosidase
activity was monitored up to 36 hours post infection. We
found out that FL expression did not affect rVACV multi-
plication in HeLa cells, as the β-galactosidase activity was
similar for all viruses at every interval (not shown).
Mouse and human cell lines of hematopoietic origin, 32D
and MOLM-9, were completely non-permissive for any of
the rVACV tested (not shown). However, a similar situa-
tion as in vivo has been observed during infection of con-
fluent culture of macrophage cell line J774.G8. In
comparison with the other double recombinants, multi-
plication of P13-βgal -E/L-FL virus in J774.G8 was
reduced as determined by β-galactosidase assay (Fig. 3A),
quantitative PCR of viral DNA (Fig. 3B) and titration of
viral progeny produced by the single recombinants (not
shown). The inhibition of FL-expressing viruses was
slightly visible also in samples with added ara-C where
only the early production of β-galactosidase occurred.
Deletion of the FL gene in P13-ΔE/L-FL resulted in resto-
ration of multiplication of the reversion mutant (Fig. 3B).
The relative multiplication of P13-βgal-E/L-FL virus,
measured as the β-galactosidase production, depends on
macrophage culture conditions. In quickly growing cells
(about 40% confluence), we observed no inhibition of
P13-βgal-E/L-FL (Fig. 3C), whereas the growth of P13-
βgal-E/L-FL virus in wells containing more than 5 × 105
J774.G8 cells was significantly restricted comparing with
P13-βgal-H5-FL or P13-E7 virus.
To determine the effect of the attenuation of P13-E/L-
FL in macrophages J774.G8 on transgene expression, we
measured sFL production by infected cells. Confluent
culture of J774.G8 cells was infected at a MOI of 2.5 and
secretion of sFL into the medium as well as the amount of
intracellular FL was measured by ELISA (Fig. 3D). We
noticed that FL production directed by the strong E/L
promoter was lower but nearly comparable with that
under the control of the H5 promoter. This result was in
accordance with the reduced multiplication of the P13-E/
L-FL recombinant in macrophage culture. The amount of
produced FL was not influenced in early phase of infec-
tion as showed bars of samples with added ara-C, which
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sFL under E/L promotor occures in replicative and
postreplicative phases of infection. The localization of FL
in infected macrophages (Fig. 1C-g, h) determined by
immunofluorescence was identical to that observed in
other tested cell types. The fluorescence signal was visible
as early as 90 minutes after infection and persisted during
the observed time interval. At 3 hours after infection, the
signal was weaker in the macrophages infected with P13-
E/L-FL compared to P13-H5-FL.
Figure 2 In vivo multiplication, sFL production and antibody response to rVACV. Groups (n = 4) of C57Bl/6 female mice were inoculated i.p. with 
1 × 106 pfu of P13-E/L-FL, P13-H5-FL or P13-E7. The ovaries and sera were collected at various intervals after infection. Replication of rVACV in the ova-
ries was determined by plaque assay (A) or by Q-PCR (B). The in vivo production of FL was measured in mouse sera by ELISA (C). To determine the 
immunogenicity of recombinants, groups of mice (n = 5) were i.p. inoculated with 1 × 106 pfu of rVACV. Five weeks later, the animals were anesthe-
sized and the serum was collected. The levels of VACV specific IgG1 or IgG2a antibodies were quantified by ELISA (D). The data were analyzed by the 
two-way ANOVA.
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In the next step, we analyzed by western blots the compo-
sition of purified intracellular mature virions (IMV) of
FL-expressing viruses, P13-H5-FL, P13-E/L-FL and dou-
ble recombinants carrying both the sFL also β-galactosi-
dase genes and of P13 parental virus (Fig. 4A) using FL
specific antibody. We found out that high sFL expression
driven by the E/L promoter resulted in the incorporation
Figure 3 Multiplication of rVACV and sFL production in macrophage cell line J774.G8. Culture of J774.G8 cells was infected with the purified 
virus at MOI of 2.5 (A, C, D) or at MOI of 0.1 (B) at 37°C for 1 hour, washed with PBS and the fresh medium with or without cytosine arabinoside (40 
μg/ml) was added. Multiplication of virus was determined as beta-galactosidase activity (A, C) or by Q-PCR (B) at indicated intervals (A, B) or 24 hours 
after infection (C). Total FL production was determined by ELISA (D).
Zurkova et al. Virology Journal 2010, 7:109
http://www.virologyj.com/content/7/1/109
Page 7 of 15of sFL in virus particles, whereas sFL incorporation was
not found if the expression was regulated by the H5 pro-
moter. The sFL band associated with virion cores had the
same size of 19 kDa as found for the low-glycosylated sFL
produced in infected cells or in cells transfected with the
expression plasmid pBSC-FL. The 25 kDa glycosylated
sFL produced in infected and transfected cells was not
detected in purified virions.
To analyze the composition of intracellular mature viri-
ons (IMV), we partitioned virions into two membrane
(M1, M2) and two core fractions (C1, C2) and analyzed
them by western blot using FL specific antibody (Fig. 4B).
The enrichment of the membrane and core fractions was
confirmed by western blot using antibodies to p16 (A14,
membrane protein), 4b (A10, core protein) and convales-
cent anti-VACV mouse serum (not shown). We found
sFL (19 kDa) predominantly in the core fractions and not
in the membrane fractions of P13-E/L-FL IMV or other
tested viruses.
To confirm the association of sFL with virions, we per-
formed the neutralization assay. In this experiment,
sucrose purified particles of the double recombinants
carrying the β-Gal gene together with FL or a control
gene were incubated with polyclonal antibody against FL
or with anti-VACV rabbit or mouse serum or non-
immune serum. The neutralization of virus infectivity
was measured as the ability to produce beta-galactosidase
in CV1 cells (Fig. 4C). The control virus P13-βgal-E7 as
well as P13-βgal-H5-FL and P13-βgal-E/L-FL viruses
were neutralized by incubation with anti-VACV mouse
or rabbit serum. Neither P13-βgal-E7 nor P13-βgal-H5-
FL was neutralized by anti-FL antibodies. The infectivity
of P13-βgal-E/L-FL virus was lowered by anti-FL anti-
bodies, but not to such an extent as as observed using the
positive anti-VACV serum.
We speculated that a portion of sFL was displayed on
the surface of IMV, and we used the same antibodies or
sera to confirm the results of the neutralization experi-
ment by direct observation of virions. Purified virions of
P13-E/L-FL or P13 viruses were incubated with sFL spe-
cific polyclonal antibody or rabbit and mouse anti-VACV
serum or non-immune serum. The virus particles were
negatively stained and examined under an electron
microscope (Fig. 4D). The anti-VACV sera were able to
aggregate viral particles of both viruses. The anti-FL anti-
body mediated aggregation of P13-E/L-FL particles but
not of the parental P13 virus.
Integration of sFL in virions is associated with aberrant 
protein composition of viral particles
As the P13-E/L-FL virions were distinct in structure from
P13-H5-FL virus particles, we looked for other differ-
ences in the protein composition. The sucrose purified
Figure 4 Incorporation of sFL into viral particles. Aliquots of the in-
dicated sucrose purified virions (A) or their solubilized and separated 
fractions (B) were analyzed by western blot using the FL specific 
BAF308 monoclonal antibody. The sample prepared from the culture 
medium of 293T cells transfected with pBSC-FL expression plasmid 
served as a positive control. To neutralize virus infectivity, the sacchar-
ose purified particles were incubated at 37°C for 1 hour with PBS, anti-
FL antibody or anti-VACV serum. The first aliquot of samples was used 
for infection of cell cultures (C). Cytosine arabinoside (40 μg/ml) was 
added for inhibition of viral replication as the positive control. The 
beta-galactosidase assay was performed after 24 hours of cultivation. 
The second aliquot of samples was applied to a formvar membrane 
coated copper grid (D). Negatively stained particles were examined 
under an electron-microscope at a magnification of 50 000×.
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protein detection above and afterwards analyzed by
Western blot using anti-VACV mouse serum (Fig. 5A).
The analysis revealed additional and missing distinct
immunodominant VACV protein bands (marked with
asterisks) in the membrane as well as in the core fractions
of P13-E/L-FL IMV in comparison with P13-H5-FL or
P13 virus. In order to uncover the differing proteins,
SDS-PAGE gels were stained with Coomassie blue (Fig.
5B) and bands were cut out from the gel and identified by
mass spectrometry (Table 1). The major membrane pro-
tein p35 (gene H3L, band 1) of P13-E/L-FL virus was
shifted in comparison with two other viruses (band 4).
Band 1 co-migrated with annexin 5. All three viruses con-
tained the membrane protein p32 (gene D8L) detected in
band 2 or 3; however, the membranes of P13 and P13-H5-
FLviruses comprised an additional form of p32 detected
as band 5. The P28K protein (gene L4R, band 6) was
absent in the enriched membrane fraction of P13-E/L-FL,
whereas P13 and P13-H5-FL contained a faint band of
this major core protein. This band was also less abundant
in the core fraction of P13-E/L-FL in comparison with
other two viruses. Furthermore the core fraction of P13-
E/L-FL virus harbored an additional hypothetical 10 kDa
viral protein (band 9) and host proteins tubulin β chain
(band 7) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (band 8).
Discussion
Several studies have shown that FL protein can inhibit
tumor growth in vivo and acts as a vaccine adjuvant.
Instead of direct FL protein administration, the produc-
tion of FL by a viral vector might result in prolonged FL
presence in the body and in improved therapeutic activity
[30].
We constructed two recombinant VACVs derived from
the Praha vaccine strain whose expression of FL was con-
trolled by the natural early H5 promoter which is impor-
tant for early antigen presentation, or by the synthetic E/L
promoter with activity at both early and late times during
VACV infection [31,32]. The original goal of our project
was to use FL-expressing viruses for stimulation of anti-
gen presenting cell activity and adaptive immunity in
tumor bearing animals. Indeed, we have shown that
immunization with VACV co-expressing sFL with the E7
protein of HPV16 as a tumor antigen inhibited the forma-
tion and growth of TC1 tumors in mice [33]. In that study
we observed that despite high expression of FL controlled
by the synthetic E/L promoter in vitro, the double recom-
binant P13-E/L-FL-SigE7LAMP induced only low levels
of FL in the serum of inoculated mice. In an attempt to
elucidate the nature of the inhibitory effect of FL overex-
pression controlled by the E/L promoter on the release of
recombinant cytokine in mouse serum, we focused on a
more detailed study of FL-producing recombinants.
The first step was to characterize the multiplication and
FL production in vitro. We compared the replication of
P13-H5-FL, P13-E/L-FL and control virus in CV1 cells by
virus progeny titration. No distinct effect of recombinant
protein expression on the replication was observed, apart
from the moderately delayed release of P13-E/L-FL virus
from infected cells. ELISA tests of media and cell lysates
of infected cultures confirmed the generally accepted
idea of the strength of natural H5 promoter of VACV
which is active mainly in the early phase of infection and
of the synthetic E/L promoter whose activity is increasing
from the early to the late phase of infection.
Figure 5 Analysis of virion protein composition. Purified P13, P13-
H5-FL or P13-E/L-FL viruses were fractionated into enriched mem-
brane and core fractions. Aliquots were separated by 12% or 8-15% 
gradient SDS-PAGE. The gel was processed by western blotting and 
stained with anti-VACV mouse serum (A) or stained with Coomassie 
blue (B). The proteins of differing bands were identified by MALDI.
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6-weeks-old mice and measured the expression of FL in
vivo for several days after inoculation. The animals inocu-
lated with P13-E/L-FL did not have highly elevated serum
levels of FL, similarly to the previous experiments done
with double recombinant P13-E/L-FL-SigE7LAMP.
Moreover, we found out, by titration and by quantitative
PCR of viral DNA in mouse ovaries, that the P13-E/L-FL
virus was not able to multiply in vivo. It was seemingly in
contradiction with our previously published results
where the expression of FL under the control of the E/L
promoter did not affect the multiplication of the double
recombinant P13-E/L-FL-SigE7LAMP in the mouse ova-
ries in comparison with the control virus and with the
double recombinant P13-H5-FL-SigE7LAMP [33]. When
comparing the double recombinant P13-E/L-FL-
SigE7LAMP with the single recombinant P13-E/L-FL in
vitro, we found the latter to produce higher levels of Flt3L
in infected CV1 cells (not shown). Decrease in FL pro-
duction by double recombinant in vitro could be ascribed
to the inactivation of the F7L locus as a result of the inser-
tion of the SigE7LAMP gene, which is known to down-
regulate the expression of the gene inserted in the TK
locus [34]. The overexpression of FL by the single recom-
binant was so high that it resulted not only in limited pro-
duction of FL in vivo but even in its decreased
multiplication in mice. The block of P13-E/L-FL multipli-
cation was confirmed by the examination of the indepen-
dently derived recombinants and by the deletion of the E/
L-FL expression cassette followed by reversion to the wt
phenotype. We checked also the DNA pattern of the
genome of all analyzed viruses using SalI, HindIII, PstI,
XhoI and KpnI endonucleases and found no obvious dif-
ferences in the restriction patterns (not shown). It was
evident that the inhibition of virus multiplication in vivo
was caused by sFL overexpression under the control of
the E/L promoter.
Attenuation of recombinant vaccinia vectors in conse-
quence of the foreign gene insertion has been described
for viruses expressing IL2 [35], IL12 [36] and IL15 [37].
The multiplication was inhibited in vivo and in lymphoid
cell lines; however, the infected fibroblasts produced the
control and cytokine-expressing viruses in equivalent
titers.
The response to VACV infection has been studied in
several species [38-40]. It has been illustrated recently in
variola primate model that poxviruses productively infect
large populations of circulating monocytes and mac-
rophages in the lymph nodes, spleen and other tissues
[41]. For our study, we selected as an in vitro target cell
model the macrophage cell line J774.G8 which supports
the growth of VACV. The multiplication of the P13-E/L-
FL virus but not of the P13-H5-FL virus was restricted in
confluent cultures of this cell line. Taken into consider-
Table 1: Virion proteins identified in membrane- and core- enriched fractions detected by SDS-PAGE and mass 
spectrometry analysis.
# band ORF Protein function (Reference) # of identified peptides
1 H3L IMV major membrane protein p35 
[50] + annexin 5
12
2 D8L IMV membrane protein p32 [54] 7
3 D8L IMV membrane protein p32 7
4 H3L IMV major membrane protein p35 13
5 D8L IMV membrane protein p32 8
6 L4R Major core protein 28 k [73] 8
7 Cellular Tubulin β chain 4




9 Putative AORFL Hypothetical 10.8 kDa [74] 3
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where the macrophages are terminally differentiated cells
that rarely divide. We also determined the level of FL
expression in J774.G8 cells by P13-H5-FL or P13-E/L-FL.
Despite the sFL expression driven by promotors of differ-
ent strengths, we found the same FL secretion level by
either virus. It could mean that the inhibition of virus
multiplication is not mediated by high level of extrinsic
FL. This fact has been supported by the failure to find any
Flt3 (CD135) molecules on the membrane of J774.G8
cells and by experimental addition of extrinsic Flt3L to
J774.G8 cells that had no effect on the multiplication of
the control P13-preS2S-βgal or P13-E7 viruses at any step
of infection.The inhibition of multiplication of P13-E/L-
FL in macrophages might be reversible since we showed
the dependence of β-galactosidase production by P13-
βgal-E/L-FL on the growing activity of cell cultures.
To exclude the possibility that apoptosis is responsible
for inefficient multiplication of P13-E/L-FL in mac-
rophages, the presence of the apoptosis marker Annexin-
V and the cleavage of PARP were determined. For these
experiments, we prepared the double recombinants
expressing both the FL gene and GFP protein and used
them for following up the early apoptosis marker
(Annexin-V) in infected cells during virus replication.
There were not significant differences among viruses in
the infectivity (GFP positive cells amount) or in Annexin-
V binding (not shown). We also tested the cleavage of
PARP protein (late apoptosis marker) in macrophages
infected by single recombinant viruses. The cleavage was
obvious in cells infected by parental virus or P13-H5-FL
and slightly in P13-E/L-FL infected macrophages. As a
control, we added ara-C to macrophages, which caused
PARP cleavage in all infected and non-infected mac-
rophages (not shown). We concluded that the attenuation
of P13-E/L-FL was not due to the enhanced apoptosis in
macrophages.
After challenging the assumption that the antiviral state
of macrophages is mediated by high levels of Flt3L pro-
duced by recombinants during infection, we considered
the possibility of changes in the elementary protein com-
position of the virion itself. The strong expression of FL
driven by the synthetic E/L promoter led to its incorpora-
tion into a core-associated protein fraction. This was due
to the strong FL expression in BSC40 or HeLa cells used
for virus stock preparation. The endoplasmic reticulum
and Golgi apparatus of P13-E/L-FL infected cells con-
tained a huge amount of FL protein. The foreign gene
product has been reported previously to be trapped in the
virion due to protein-protein interactions during the
virion assembly process [42-44]. Bereta et al. have indi-
rectly shown that the rVV expressing CD40L gene con-
tains biologically active CD40L protein in particles [45]
However, there is some selectivity in the encapsidation
process. There is evidence of the incorporation of recom-
binant protein into one or more virion compartments.
Vaccinia virus expressing the bacterial CAT gene incor-
porated the enzyme into the virus particle [46]. The
expression of the cytokine IL-12 led to the incorporation
of about 0.01% of the total recombinant protein into an
envelope fraction, HIV1 env (gp160-120) was tightly
bound in protein-DNA complexes, and the enzyme beta-
galactosidase was found exclusively in core-associated
fraction [47]. Transport and sorting of viral proteins
directly from the endoplasmic reticulum into the growing
immature virions using non-COPII vesicles [48] could
explain selective integration of the low-glycosylated FL
into P13-E/L-FL virions. A similar selectivity for the inte-
gration of non-glycosylated form of a glycoprotein into
the membrane of IMV particles was observed for A14
[49]. However, FL was not incorporated into a membrane
fraction, but it was tightly bound to core, although it was
also exposed on the surface of IMV to offer the epitopes
for anti-FL antibodies as verified by neutralization assays
and proven by electron microscopy. Moreover, the local-
ization of the recombinant proteins may be facilitated by
specific protein-protein interactions. Variation in the
localization of recombinant protein has been reported in
double recombinants expressing the protein of interest
and β-galactosidase [47]. We also analysed the FL distri-
bution also in double recombinant viruses P13-βgal-H5-
FL and P13-βgal -E/L-FL and found no changes in com-
parison with the single recombinant viral particles.
In the present study, we have shown that the integra-
tion of sFL into the IMV virions was associated with an
altered composition of the virions. We observed that P13-
E/L-FL virions contained H3L of a higher molecular
weight than P13 or P13-H5-FL (lanes 1 and 4). The H3
protein is an immunodominant component of IMV, binds
to heparansulphate and is found in IMV in two isoforms,
(1-324 aa) and (48-324 aa) [50]. Both the full length pro-
tein and N-terminally deleted form can be incorporated
into the viral membrane [51] although the specific func-
tions of the H3 isoforms are yet not known. As the H3
protein is nonessential for virus multiplication in cell
monolayers [52], the integration of FL into the virion
might modify the ratio of H3 isoforms. Similarly to H3,
the second differently displayed virion component, the
D8 protein, plays the role as the glycosaminoglycan
(GAG) binding molecule [53]. It has been shown, that the
D8 protein integrated into the viral particle can be
cleaved by trypsin without any decrease of virus infectiv-
ity [54]. The D8 protein detected in band 5 could be a
cleavage product of trypsin like protease. The unusual
forms of both GAG binding structures resulting from
high FL gene expression may influence the growth of
virus in some cell types. Differences in these two mem-
brane proteins in association with FL gene expression
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affects the composition of the IMV core. The pattern of
core proteins showed multiple band changes. One domi-
nant band contains the p28K protein encoded by L4R.
This protein is a basic DNA binding protein and plays an
essential role in virus replication. The protein fragment
(33-251 aa) produced by Ala-Gly-specific cleavage is usu-
ally found in the virus core in the absence of its precursor
[55]. P13-E/L-FL virions contain less P28K than P13 or
P13-H5-FL. As we did not analyze the adjacent bands, we
cannot say whether or not decrease in the cleaved form of
the L4 protein is associated with the presence of the P28K
precursor in purified virions. There are reduced levels of
early RNA and protein production in cells infected by
L4R deficient vaccinia virus particles [56], which could
also explain decreased levels of mRNA throughout the
course of macrophage infection by P13-E/L-FL virus
(data not shown). P13-E/L-FL virions yielded additional
bands containing host proteins. Tubulin β chain has been
found previously in non-recombinant vaccinia virus IMV
where it can form up to 0.7% of protein content [57]. We
found an increased amount of tubulin β chain in the core
fraction together with increased FL in P13-E/L-FL.
MALDI analysis of the core fraction yielded GAPDH.
This enzyme, which is involved in many different cellular
processes, has also been found incorporated in human
immunodeficiency virus type 1 (HIV-1) virions [58].
GAPDH binds actin filaments in vitro [59] and therefore
could be incorporated in the complex with actin. Actin
has been identified in virions of VACV [57] several other
DNA viruses and HIV.
Conclusions
The expression of FL highly influenced the behavior of
recombinant vaccinia virus in dependence on the level of
its expression. The production of FL driven by the strong
synthetic promoter resulted in decreased growth of P13-
E/L-FL in confluent macrophage cell line as well as in its
limited multiplication in vivo when inoculated in mice.
The specificity of the effect of high FL levels on virus
multiplication was confirmed using the reversion mutant.
The inhibition of in vivo replication was mirrored in the
level of antibodies against vaccinia virus. A strong FL
expression in CV1 and HeLa cells changed not only the
host range of the recombinant but also the basic protein
contents of virions. The major proteins - H3L and D8L -
which are responsible for the virus binding to the cells,
and 28 K protein that serves as a virulence factor were
changed in the membrane portion of P13-E/L-FL viral
particles. There also were changes in the core portion as a
consequence of poorer protein processing (multiple
larger, uncleaved proteins in comparison with the control
virus) and the increased content of cellular proteins. The
overexpression of FL also resulted in its incorporation
into the viral core of P13-E/L-FL IMV particles. In con-
trary to the equimolar ratio of the glycosylated to the
non-glycosylated form of FL in transfected cells, the
recombinant virus incorporated mainly the smaller, non-
glycosylated FL. We have shown that the overexpression




The pHUFLT3L plasmid containing the coding sequence
of the soluble isoform of FL (ID number - U29874) was
obtained from Immunex (now the part of Amgen Inc.).
The plasmids pSC59-H5-FL and pSC59-E/L-FL have
been described earlier [33]. The expression plasmid
pBSC-FL was prepared by ligation of an EcoRI fragment
of pHUFLT3L plasmid carrying the FL coding sequence
with the pBSC plasmid [60] cleaved with the same
enzyme. The pTK+ plasmid was derived from pGS20 [61]
by excision of the EcoRI fragment. The pD357 plasmid
[62] containing an E.coli β-galactosidase gene under the
control of the P7.5 promoter was used for replacement of
the C23L and B29R genes by the β-galactosidase gene
Viruses
Vaccinia virus strain Praha, clone 13 [63] was used as the
parental virus. Single recombinants P13-H5-FL and P13-
E/L-FL were prepared by the insertion of FL gene into
thymidine kinase using plasmids pSC59-H5-FL and
pSC59-E/L-FL, respectively, followed by selection in
medium supplemented with bromodeoxyuridine. The
double recombinants P13-βgal-H5-FL and P13-βgal-E/L-
FL were prepared by the insertion of β-galactosidase into
the FL-expressing single recombinants using pD357 plas-
mid and by the selection of the virus forming stable blue
plaques after three purification steps. The revertant virus
P13-ΔE/L-FL was prepared using the pTK+ plasmid car-
rying the functional thymidine kinase gene; the selection
occurred in 143B cells grown in HAT supplemented E-
MEM medium. Virus P13-E7 carrying the E7 early pro-
tein of HPV16 has been described earlier [64]. Virus P13-
βgal-pS2S was derived from P13-pS2S [65] using pD357
plasmid. Viruses were grown in BSC40 cells, purified by
sucrose-gradient centrifugation [66] and titrated in CV-1
cells. The number of virus particles was determined from
the optical density measured at 260 nm using the formula
1 U of OD260 nm = 1.2 × 1010 viral particles/ml [67]. The
ratio was comparable for all the viruses used in the exper-
iments.
Cell lines
CV-1 and BSC-40 African green monkey kidney cell lines
were grown in Modified E-MEM medium (EPL, SEVAP-
HARMA, Prague) containing bovine serum growth-
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embryonic kidney 293T cells [69]kindly provided by J.A.
Kleinschmidt, DKFZ, Heidelberg, Germany, human HeLa
cell line and J774.G8 mouse macrophage cell line were
grown in DMEM (PAA Laboratories, Linz, Austria) sup-
plemented with 10% fetal bovine serum (FBS; PAA Labo-
ratories). The cell lines MOLM9 and 32D were grown in
RPMI-1640 medium (Sigma, Saint Louis, MO) supple-
mented with 10% FBS. The 143B cell line was maintained
in E-MEM medium (SEVAPHARMA, Prague) supple-
mented with 10% FBS. Each medium contained 2 mM L-
glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin.
Mice
Six-week-old C57Bl/6 (H-2b) female mice were obtained
from Charles River, Germany. Animals were maintained
under standard conditions at the National Institute of
Public Health (Prague). The experiments were performed
in compliance with Acts Nos. 246/92 and 77/2004 on ani-
mal protection against cruelty and Decree No. 311/97 of
the Ministry of Health of the Czech Republic, on the care
and use of experimental animals. Mice were injected
intraperitoneally (i.p.) with 0.5 ml PBS containing soni-
cated suspension of sucrose-purified particles of rVACV.
Mice were anesthetized with halothane (Narcotane, Léc-
iva, Praha) and carotid blood was collected at indicated
time intervals.
ELISA
FL was quantified with an Flt3 ligand ELISA detection kit
(R&D Systems GmBH, Wiesbaden-Nordenstadt, Ger-
many) using the capture mouse monoclonal antibody
MAB608 (100 ng/well), biotinylated detection goat poly-
clonal antibody BAF308 (7.5 ng/well), streptavidin-HPR
(1:250) or avidin-HPR (1:1000) complex, both obtained
from Pharmingen (BD Biosciences, Erembodegem, Bel-
gium), and TMB substrate solution for visualization of
the reaction. Samples were measured by an ELISA reader
at 450 nm. Standard Flt3 ligand protein (PeproTech EC
Ltd, London, UK) was diluted to 500-7,5 pg/ml. Detec-
tion of VACV-specific antibodies has been described ear-
lier [70].
SDS-PAGE and western blot
Infected cells or purified viral particles were extracted
with denaturing, reducing sample buffer [71]. Samples
were separated by SDS-PAGE in 10% or 12% gels. Pro-
teins were blotted onto a nitrocellulose membrane
(Hybond-C Extra, Amersham) and after blocking with
10% skimmed dry milk in PBS, the membrane was incu-
bated with primary antibody BAF308 (anti-FL, R&D Sys-
tems GmBH, Wiesbaden-Nordenstadt, Germany) diluted
1:500 or convalescent mouse serum (anti-VACV) diluted
1:50 - 1:100. After washing, the membrane was incubated
with rabbit anti-mouse IgG horseradish-peroxidase-con-
jugated secondary antibody (Sigma-Aldrich, Steinheim,
Germany). Proteins were visualized with the ECL Plus
system (Amersham).
Mass spectrometry and protein identification
Electrophoretic gels were stained with Coomassie blue.
Selected spots on the preparative gels were excised and
destained using 50% acetonitrile in 25 mM ammonium
bicarbonate, dehydrated with 200 μl of acetonitrile for 5
min at 30°C and then vacuum-dried (SpeedVac, Thermo
Scientific, Waltham, Ma). Gel pieces were rehydrated and
proteins were digested for 8 hours at 37°C with 30 ng/μl
trypsin (Trypsin Gold Mass Spectrometry Grade, Pro-
mega, Madison, WI) in 25 mM ammonium bicarbonate.
After digestion, peptides were extracted from gel pieces
using step by step extraction with an acetonitrile gradient
(15%-60% acetonitrile with 1% trifluoroacetic acid) using
sonicator (Elma, Singen, Germany) cooled with ice cubes.
Extracted peptides were concentrated in SpeedVac.
MALDI mass spectrometry (MALDI/MS) peptide mass
fingerprint analysis was used to characterize the digests.
The MALDI/MS was performed in a Refelex IV MALDI-
TOF mass spectrometer (Bruker). Data were processed
by proteomic software Mascot.
Beta-galactosidase assay
Beta-galactosidase activity was determined according to
Miller [72]. The samples of infected cells were frozen and
thawed and then centrifuged to remove cellular debris.
Beta-galactosidase activity of cell extracts was measured
by a colorimetric assay using o-nitrophenyl β-D-galacto-
pyranoside (ONPG). The absorbance of samples was
determined at 450 nm.
Virus neutralization
Sonicated, sucrose purified virus particles were incubated
in a minimal volume of PBS, with 0.5 μg of rabbit poly-
clonal antibody against FL (MBL, Woburn, MA) or with
rabbit and mouse anti-VACV serum or negative serum.
After a 1-hour-incubation at 37°C, the viruses were used
for the infection of confluent cell layers or for the prepa-
ration of electron-microscopy samples.
Electron microscopy
Metal grids were freshly coated with a Formvar (polyvi-
nylformal, Serva) membrane. Five to ten μl of viral sus-
pension (sonicated or antibody-treated) were absorbed to
the grid for 10 min and then washed twice with water and
twice with 1% phosphowolframic acid, pH 9.0, each time
for 1 min. The samples were observed by transmission
electron microscope JEM1011 (JEOL, Tokyo, Japan) at
indicated magnifications.
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The cell monolayer grown on a round glass plate was
infected with virus at a MOI of 2 at 37°C for 30 minutes.
The inoculum was then removed and cells were culti-
vated in DMEM. At time intervals not longer than 12
hours post infection (h.p.i.), the cells were washed with
cold PBS, fixed for 10 minutes in 4% paraformaldehyde
(PA) and permeabilized for 10 minutes in 2% PA with 1%
Triton-X100. The remaining PA was neutralized by incu-
bation of samples with 0.1 M glycine in PBS for 10 min-
utes. After blocking in 10% skimmed dry milk in PBS for
30 minutes, samples were incubated with anti-FL
MAB608 (diluted 1:500) and with anti-GM130 or with
anti-calreticulin (both diluted 1:100; Santa Cruz Biotech-
nology) in 5% dry milk in PBS for 30 minutes, washed five
times (PBS, 0.2% Tween 20) and incubated with second-
ary antibody against mouse IgG labeled with Alexa fluor
488 and/or with antibody against rabbit IgG labeled with
Alexa fluor 546 (Invitrogen, USA), diluted 1:500 in 5% dry
milk in PBS for 30 minutes and counterstained with 1 μg/
ml propidium iodide or DAPI (Sigma-Aldrich Gmbh,
Munich, Germany). The washed plates were observed by
Nikon E600 fluorescence microscope for green, red and
blue signals at a magnification of 1000×.
Fractionation of viral proteins
Virion samples containing equal amounts of proteins
(determined by the Bradford protein assay, BioRad) were
incubated in 50 mM Tris-buffer with 10 mM MgCl2, pH
8.5, at 37°C for 30 minutes and subsequently supple-
mented with detergents for solubilization of two mem-
brane and two core fractions (soluble lipid envelope
fraction "M1", protein-matrix-like "M2", soluble core "C1"
and DNA-core fraction "C2") [47]. As the supplements
for the membrane and core fractions, 1% NP-40 or 1%
NP-40 plus 50 mM DTT and 0.5%DOC plus 0.1% SDS or
Laemmli buffer were used, respectively. Each fraction was
separated from insoluble proteins by centrifugation at
13000 g for 10 min.
Quantitative PCR (Q-PCR)
Mice were anaesthetized with halothane (Narcotan, Léc-
iva, Praha) and sacrificed. The ovaries were dissected,
washed in PBS and homogenized. DNA was extracted
using DNeasy Tissue Kit (Qiagen). Real-time quantitative
PCR was performed as described previously [33].
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